Early therapeutic interventions in inflammatory rheumatic diseases have proven successful in inducing drug-free remission, and EULAR – The European Alliance of Associations for Rheumatology – recommends early intervention in arthritis, since conventional synthetic disease-modifying antirheumatic drugs (csDMARD) have been shown to slow disease progression in both rheumatoid and psoriatic arthritis.